These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

48 related articles for article (PubMed ID: 1426207)

  • 21. Bronchodilator actions of xanthine derivatives administered by inhalation in asthma.
    Cushley MJ; Holgate ST
    Thorax; 1985 Mar; 40(3):176-9. PubMed ID: 3983884
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Trials of the bronchodilator activity of the isoenzyme-selective phosphodiesterase inhibitor AH 21-132 in healthy volunteers during a methacholine challenge test.
    Foster RW; Rakshi K; Carpenter JR; Small RC
    Br J Clin Pharmacol; 1992 Dec; 34(6):527-34. PubMed ID: 1493085
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sensitive determination of the phosphodiesterase III/IV inhibitor zardaverine in human serum by direct sample injection, automated precolumn clean-up and high-performance liquid chromatography.
    Huber R; Schildnitz U
    J Chromatogr; 1991 Aug; 553(1-2):65-70. PubMed ID: 1787170
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enprofylline--effects of a new bronchodilating xanthine derivative in asthmatic patients.
    Laursen LC; Johannesson N; Dirksen A; Djurup R; Munch EP; Taudorf E; Weeke B
    Allergy; 1983 Jan; 38(1):75-9. PubMed ID: 6340552
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cytotoxicity of Zardaverine in Embryonal Rhabdomyosarcoma from a Costello Syndrome Patient.
    Cartledge DM; Robbins KM; Drake KM; Sternberg R; Stabley DL; Gripp KW; Kolb EA; Sol-Church K; Napper AD
    Front Oncol; 2017; 7():42. PubMed ID: 28421158
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of the Neuroimmune Modulator Ibudilast for the Treatment of Alcoholism: A Randomized, Placebo-Controlled, Human Laboratory Trial.
    Ray LA; Bujarski S; Shoptaw S; Roche DJ; Heinzerling K; Miotto K
    Neuropsychopharmacology; 2017 Aug; 42(9):1776-1788. PubMed ID: 28091532
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A short review on structure and role of cyclic-3',5'-adenosine monophosphate-specific phosphodiesterase 4 as a treatment tool.
    Eskandari N; Mirmosayyeb O; Bordbari G; Bastan R; Yousefi Z; Andalib A
    J Res Pharm Pract; 2015; 4(4):175-81. PubMed ID: 26645022
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of phosphodiesterase 4 modulates cytokine induction from toll like receptor activated, but not rhinovirus infected, primary human airway smooth muscle.
    Van Ly D; De Pedro M; James P; Morgan L; Black JL; Burgess JK; Oliver BG
    Respir Res; 2013 Nov; 14(1):127. PubMed ID: 24237854
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dual PDE3/4 inhibitors as therapeutic agents for chronic obstructive pulmonary disease.
    Banner KH; Press NJ
    Br J Pharmacol; 2009 Jul; 157(6):892-906. PubMed ID: 19508401
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phosphodiesterase 3 inhibition and cough in elderly asthmatics.
    Ishiura Y; Fujimura M; Nobata K; Abo M; Oribe T; Myou S; Nakamura H
    Cough; 2005 Nov; 1():11. PubMed ID: 16307683
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phosphodiesterase-4 inhibitors in the treatment of inflammatory lung disease.
    Spina D
    Drugs; 2003; 63(23):2575-94. PubMed ID: 14636078
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetic and pharmacodynamic profile following oral administration of the phosphodiesterase (PDE)4 inhibitor V11294A in healthy volunteers.
    Gale DD; Landells LJ; Spina D; Miller AJ; Smith K; Nichols T; Rotshteyn Y; Tonelli A; Lacouture P; Burch RM; Page CP; O'Connor BJ
    Br J Clin Pharmacol; 2002 Nov; 54(5):478-84. PubMed ID: 12445026
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phosphodiesterase 4 inhibitors and the treatment of asthma: where are we now and where do we go from here?
    Giembycz MA
    Drugs; 2000 Feb; 59(2):193-212. PubMed ID: 10730545
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of selective phosphodiesterase 3 inhibition on the early and late asthmatic responses to inhaled allergen.
    Bardin PG; Dorward MA; Lampe FC; Franke B; Holgate ST
    Br J Clin Pharmacol; 1998 Apr; 45(4):387-91. PubMed ID: 9578187
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Asthma.
    Calverley PM
    Postgrad Med J; 1996 Jan; 72(843):12-8. PubMed ID: 8746278
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cyclic nucleotide phosphodiesterases in the human lung.
    Dent G; Magnussen H; Rabe KF
    Lung; 1994; 172(3):129-46. PubMed ID: 8201828
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of bronchospastic disorders in the 1990s. What does the future hold?
    Gianaris PG; Golish JA
    Drugs; 1993 Jul; 46(1):1-6. PubMed ID: 7691502
    [No Abstract]   [Full Text] [Related]  

  • 38. Bronchodilatory effect of inhaled zardaverine, a phosphodiesterase III and IV inhibitor, in patients with asthma.
    Brunnée T; Engelstätter R; Steinijans VW; Kunkel G
    Eur Respir J; 1992 Sep; 5(8):982-5. PubMed ID: 1426207
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pulmonary function and airway responsiveness in mild to moderate asthmatics given repeated inhaled doses of zanamivir.
    Cass LM; Gunawardena KA; Macmahon MM; Bye A
    Respir Med; 2000 Feb; 94(2):166-73. PubMed ID: 10714424
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD). Dutch Study Group.
    Maesen FP; Smeets JJ; Sledsens TJ; Wald FD; Cornelissen PJ
    Eur Respir J; 1995 Sep; 8(9):1506-13. PubMed ID: 8575576
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.